{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-194863","form_type":"8-K","ticker":"TEM","cik":"0001717115","company_name":"Tempus AI, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.245306+00:00","generated_at":"2026-05-31T12:26:39.318160+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tempus Q2 revenue $166M, up 25% YoY; guides FY2024 revenue ~$700M","bullets":["Revenue $166.0M (+25% YoY); data licensing grew 40% YoY; genomics revenue $112.3M (+22.2%).","Net loss ($552.2M) largely from $493.1M stock compensation and payroll taxes tied to IPO.","Adjusted EBITDA ($31.2M), improved $12.7M QoQ from Q1; Non-GAAP genomics margin 49.4% (+50bps).","FY2024 revenue guidance ~$700M (~32% growth); adjusted EBITDA guided at ~($105M), improvement of ~$50M.","Launched MRD assays, JV with SoftBank for Japan, FDA 510(k) for ECG-AF device, CMS ADLT status for xT CDx."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-194863","json":"https://secwatch.observer/filing/0001193125-24-194863.json","markdown":"https://secwatch.observer/filing/0001193125-24-194863.md","text":"https://secwatch.observer/filing/0001193125-24-194863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1717115/000119312524194863/0001193125-24-194863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1717115/000119312524194863/d878812d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:26:39.318160+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}